You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Chapter title |
Optimization of CAT-354, a Therapeutic Antibody Directed Against Interleukin-13, Using Ribosome Display.
|
|---|---|
| Chapter number | 22 |
| Book title |
Ribosome Display and Related Technologies
|
| Published in |
Methods in molecular biology, January 2012
|
| DOI | 10.1007/978-1-61779-379-0_22 |
| Pubmed ID | |
| Book ISBNs |
978-1-61779-378-3, 978-1-61779-379-0
|
| Authors |
George Thom, Ralph Minter |
| Abstract |
In this case study, we describe the use of in vitro protein evolution with ribosome display to improve the potency of a human interleukin-13-neutralising antibody by a factor of over 200-fold and derive a therapeutic candidate, CAT-354, for the treatment of asthma. A combination of directed and random mutagenesis enabled the identification of highly potent neutralising antibodies and highlighted the advantage of the ribosome display protein evolution approach in identifying beneficial mutations across the entire sequence space. This chapter describes in detail the process followed to achieve a successful in vitro affinity maturation outcome using ribosome display technology. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 31% |
| Researcher | 4 | 31% |
| Other | 3 | 23% |
| Unknown | 2 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 54% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Immunology and Microbiology | 1 | 8% |
| Engineering | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 2 | 15% |